跳至主要内容
临床试验/NL-OMON55682
NL-OMON55682招募中4 期

Pharmacogenetics Use For Further treatment Improvement in childreN - PUFFI

Academisch Medisch Centrum0 个研究点目标入组 100 人开始时间: 待定最近更新:
适应症

试验速览

阶段
4 期
状态
招募中
入组人数
100

研究概览

简要总结

Trial is onging in other countries

研究设计

研究类型
Interventional

入排标准

年龄范围
2 至 17(—)

入选标准

  • - Between 6-18 years of age
  • - Doctor's diagnosis of asthma based on patient history, FEV1 reversibility >=
  • 12% ever and/or bronchial hyperresponsiveness ever.
  • - Current asthma symptoms (based on ACT (>= 12 years) or c-ACT (< 12 years)
  • score <= 19
  • - ICS use >= 3 months before inclusion (start dosage ICS, treatment step 2
  • according to childhood asthma guideline NVK)
  • - Adequate inhalation technique
  • - self-assessed good adherence to maintenance asthma treatment
  • - understanding of Dutch language
  • - Internet access at home, willing to fill in internet questionnaires

排除标准

  • - active smoking
  • - congenital heart disease
  • - serious lung disease other than asthma
  • - LABA use in the past 6 months
  • - omalizumab use
  • - ICU admission in the previous year

研究者

相似试验